BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Inspira™ Announces Program to Pioneer the Applicable Use of the INSPIRA™ ART100 Device for an Artificial Womb

  Inspira™ Technologies OXY B.H.N. Ltd. is delighted to announce the commencement of a program to explore the applicable use of the INSPIRA™ ART100 Device for an artificial womb for neonates in need of vital respiratory support.

  April 3, 2024

   · 

  3 min read
• Biotech Beach

  ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)

  ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) announced today that it has submitted its response to the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for neffy® (epinephrine nasal spray), for the treatment of Type I allergic reactions including anaphylaxis.

  April 3, 2024

   · 

  5 min read
• Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024

  Aytu BioPharma, Inc. today announced that its CEO, Josh Disbrow, will be participating in the Emerging Growth Conference.

  April 3, 2024

   · 

  1 min read
• InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

  InspireMD, Inc. today announced that Marvin Slosman, Chief Executive Officer, will deliver a company update presentation at the 23rd Annual Needham Virtual Healthcare Conference, which is being held April 8-11, 2024.

  April 3, 2024

   · 

  1 min read
• Therapeutic Potential of CD20 x CD3 Bispecific Antibodies

  On Monday, March 25th, 2024, the U.S. FDA declined approval for Regeneron’s Odronextamab for two forms of lymphoma due to concerns over the progress of ongoing confirmatory trials.

  April 3, 2024

   · 

  2 min read
• Biotech Beach

  Dexcom Publishes Annual Sustainability Report - April 03, 2024

  DexCom, Inc., the leader in real-time continuous glucose monitoring for people with diabetes, released its annual Sustainability Report.

  April 3, 2024

   · 

  2 min read
• BioMidwest

  LIB Therapeutics To Participate in Piper Sandler Virtual Cardio Day Focused on Highlights from ACC 2024 Conference

  LIB Therapeutics Inc. today announced that David Cory, CEO, and Evan Stein, MD, PhD, COO / CSO, will participate in a virtual fireside chat at the Piper Sandler Virtual Cardio Day on April 10, 2024 at 10:30 AM ET.

  April 3, 2024

   · 

  2 min read
• Biotech Bay

  XOMA Corporation Announces Closing of Tender Offer

  XOMA Corporation announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of Kinnate Biopharma Inc.

  April 3, 2024

   · 

  5 min read
• BioCapital

  Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024

  Shuttle Pharmaceuticals Holdings, Inc. today announced that its Chief Executive Officer, Dr. Anatoly Dritschilo, will be participating in the Emerging Growth Conference.

  April 3, 2024

   · 

  2 min read
• Policy

  IASO Bio Announces U.S. FDA Approval of Investigational New Drug Application for BCMA CAR-T Equecabtagene Autoleucel for Generalized Myasthenia Gravis

  IASO Biotechnology is pleased to announce that the Investigational New Drug application for its BCMA CAR-T has been approved by the U.S. Food and Drug Administration for use in U.S. clinical trials for generalised myasthenia gravis.

  April 3, 2024

   · 

  5 min read